NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, the mechanisms between Nrf2 and TrxR in CML and imatinib-resistant CML are likely to be complex, and the effects of various factors may be different depending on the cell environment and redox state.